| scholarly article | Q13442814 |
| P2093 | author name string | Ai-Ming Yu | |
| Hong-Wu Shen | |||
| Xi-Ling Jiang | |||
| P2860 | cites work | Differential contributions of serotonin receptors to the behavioral effects of indoleamine hallucinogens in mice | Q24594834 |
| Development of a LC-MS/MS method to analyze 5-methoxy-N,N-dimethyltryptamine and bufotenine, and application to pharmacokinetic study | Q24601816 | ||
| Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens | Q24620764 | ||
| Psychedelic 5-Methoxy-N,N-Dimethyltryptamine: Metabolism, Pharmacokinetics, Drug Interactions, and Pharmacological Actions | Q24633393 | ||
| Animal models of the serotonin syndrome: a systematic review | Q27010038 | ||
| Identification of the substrate binding region of vesicular monoamine transporter-2 (VMAT-2) using iodoaminoflisopolol as a novel photoprobe | Q27863370 | ||
| WAY-100635 is a potent dopamine D4 receptor agonist | Q28258364 | ||
| Serotonin syndrome: recognition and treatment | Q44158916 | ||
| Contribution of individual cytochrome P450 isozymes to the O-demethylation of the psychotropic beta-carboline alkaloids harmaline and harmine. | Q44370451 | ||
| Alpha-methyltryptamine revisited via easy Internet access. | Q44459868 | ||
| Screening for endogenous substrates reveals that CYP2D6 is a 5-methoxyindolethylamine O-demethylase | Q44460548 | ||
| Monoamine oxidase inhibitor poisoning resulting from Internet misinformation on illicit substances | Q44949973 | ||
| New drugs of abuse update: Foxy Methoxy | Q45081674 | ||
| Dimethyltryptamine (DMT): prevalence, user characteristics and abuse liability in a large global sample | Q45383954 | ||
| Bioanalytical and clinical evaluation of 103 suspected cases of intoxications with psychoactive plant materials. | Q45935490 | ||
| Pharmacological characterization of harmaline-induced tremor activity in mice. | Q45982456 | ||
| High-affinity binding of beta-carbolines to imidazoline I2B receptors and MAO-A in rat tissues: norharman blocks the effect of morphine withdrawal on DOPA/noradrenaline synthesis in the brain | Q46629739 | ||
| Foxy methoxy: a new drug of abuse. | Q46856269 | ||
| A fatal poisoning with 5-methoxy-N,N-diisopropyltryptamine, Foxy | Q46889621 | ||
| Adult siRNA-induced knockdown of mGlu7 receptors reduces anxiety in the mouse | Q48027955 | ||
| Tremorigenic effect and inhibition of tryptamine and serotonin receptor binding by beta-carbolines | Q48233472 | ||
| Central serotonin level-dependent changes in body temperature following administration of tryptophan to pargyline- and harmaline-pretreated rats | Q48788728 | ||
| On the role of brain 5-HT7 receptor in the mechanism of hypothermia: comparison with hypothermia mediated via 5-HT1A and 5-HT3 receptor | Q48922479 | ||
| Lu AF21934, a positive allosteric modulator of mGlu4 receptors, reduces the harmaline-induced hyperactivity but not tremor in rats. | Q50247812 | ||
| The Serotonin Syndrome | Q55871784 | ||
| The paradox of 5-methoxy-N,N-dimethyltryptamine: an indoleamine hallucinogen that induces stimulus control via 5-HT1A receptors | Q73363254 | ||
| Evidence for functional interactions between 5-HT1A and 5-HT2A receptors in rat thermoregulatory mechanisms | Q74467746 | ||
| Modulation of phencyclidine-induced changes in locomotor activity and patterns in rats by serotonin | Q74506058 | ||
| Serotonin potentiates sympathetic responses evoked by spinal NMDA | Q80264241 | ||
| Cold-activated brown adipose tissue in healthy men | Q29547382 | ||
| Clinical toxicology of newer recreational drugs | Q30407755 | ||
| Enhanced effects of amphetamine but reduced effects of the hallucinogen, 5-MeO-DMT, on locomotor activity in 5-HT(1A) receptor knockout mice: implications for schizophrenia | Q30445688 | ||
| JL13 has clozapine-like actions on thermoregulatory cutaneous blood flow in rats: Involvement of serotonin 5-HT1A and 5-HT2A receptor mechanisms. | Q33514157 | ||
| Methodology for and the determination of the major constituents and metabolites of the Amazonian botanical medicine ayahuasca in human urine. | Q33740814 | ||
| Effects of monoamine oxidase inhibitor and cytochrome P450 2D6 status on 5-methoxy-N,N-dimethyltryptamine metabolism and pharmacokinetics | Q33887065 | ||
| Modification of the effects of 5-methoxy-N,N-dimethyltryptamine on exploratory behavior in rats by monoamine oxidase inhibitors | Q34087847 | ||
| Pharmepéna-Psychonautics: Human intranasal, sublingual and oral pharmacology of 5-methoxy-N,N-dimethyl-tryptamine | Q34112472 | ||
| Schedules of controlled substances: placement of 5-methoxy-N,N-dimethyltryptamine into Schedule I of the Controlled Substances Act. Final rule | Q34155717 | ||
| The effect of memantine in harmaline-induced tremor and neurodegeneration. | Q34189781 | ||
| High-affinity agonist binding is not sufficient for agonist efficacy at 5-hydroxytryptamine2A receptors: evidence in favor of a modified ternary complex model | Q34415673 | ||
| A fatal intoxication following the ingestion of 5-methoxy-N,N-dimethyltryptamine in an ayahuasca preparation | Q34476705 | ||
| Thermoregulatory responses to serotonin (5-HT) receptor stimulation in the rat. Evidence for opposing roles of 5-HT2 and 5-HT1A receptors | Q34562816 | ||
| The roles of 5-HT1A and 5-HT2 receptors in the effects of 5-MeO-DMT on locomotor activity and prepulse inhibition in rats | Q34570539 | ||
| Ability of ketanserin to block different receptors in human placental vessels. | Q34659114 | ||
| The natural hallucinogen 5-MeO-DMT, component of Ayahuasca, disrupts cortical function in rats: reversal by antipsychotic drugs | Q34660497 | ||
| Inhibition of monoamine oxidase A by beta-carboline derivatives | Q34737351 | ||
| Nonlinear pharmacokinetics of 5-methoxy-N,N-dimethyltryptamine in mice | Q35079542 | ||
| Stimulus control by 5-methoxy-N,N-dimethyltryptamine in wild-type and CYP2D6-humanized mice | Q35085860 | ||
| Clinical investigations of the therapeutic potential of ayahuasca: rationale and regulatory challenges | Q35784312 | ||
| Schedules of controlled substances: placement of alpha-methyltryptamine and 5-methoxy-N,N-diisopropyltryptamine into schedule I of the Controlled Substances Act. Final rule. | Q35904580 | ||
| The pathophysiology of serotonin toxicity in animals and humans: implications for diagnosis and treatment | Q36292734 | ||
| Brown adipose tissue sympathetic nerve activity is potentiated by activation of 5-hydroxytryptamine (5-HT)1A/5-HT7 receptors in the rat spinal cord | Q36569699 | ||
| Pharmacokinetic interactions between monoamine oxidase A inhibitor harmaline and 5-methoxy-N,N-dimethyltryptamine, and the impact of CYP2D6 status | Q36776603 | ||
| Central control of thermogenesis in mammals | Q36812556 | ||
| Potential role of CYP2D6 in the central nervous system | Q37112464 | ||
| Behavioral effects of α,α,β,β-tetradeutero-5-MeO-DMT in rats: comparison with 5-MeO-DMT administered in combination with a monoamine oxidase inhibitor | Q37230473 | ||
| Effects of CYP2D6 status on harmaline metabolism, pharmacokinetics and pharmacodynamics, and a pharmacogenetics-based pharmacokinetic model | Q37309305 | ||
| Recognizing serotonin toxicity in the pediatric emergency department | Q38032090 | ||
| Overview of serotonin syndrome | Q38059213 | ||
| Brown adipose tissue in adult humans: a metabolic renaissance | Q38095425 | ||
| Emerging psychoactive substance use among regular ecstasy users in Australia | Q39668901 | ||
| Prolonged delusional state triggered by repeated ingestion of aromatic liquid in a past 5-methoxy-N, N-diisopropyltryptamine abuser | Q40138770 | ||
| Activation but not blockade of GABAB receptors during early-life alters anxiety in adulthood in BALB/c mice | Q40233997 | ||
| On the mechanism of anti-hyperthermic effects of LY379268 and LY487379, group II mGlu receptors activators, in the stress-induced hyperthermia in singly housed mice | Q40314677 | ||
| The CYP2D6 humanized mouse: effect of the human CYP2D6 transgene and HNF4alpha on the disposition of debrisoquine in the mouse. | Q40674439 | ||
| PPI deficit induced by amphetamine is attenuated by the histamine H1 antagonist pyrilamine, but is exacerbated by the serotonin 5-HT2 antagonist ketanserin | Q42919813 | ||
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | N,N-dimethyl-5-methoxytryptamine | Q570757 |
| P1104 | number of pages | 10 | |
| P304 | page(s) | 342-351 | |
| P577 | publication date | 2015-02-01 | |
| P1433 | published in | Neuropharmacology | Q15332439 |
| P1476 | title | Potentiation of 5-methoxy-N,N-dimethyltryptamine-induced hyperthermia by harmaline and the involvement of activation of 5-HT1A and 5-HT2A receptors | |
| P478 | volume | 89 |
| Q38626654 | Behavioral Changes Over Time Following Ayahuasca Exposure in Zebrafish |
| Q37302207 | Development of a mechanism-based pharmacokinetic/pharmacodynamic model to characterize the thermoregulatory effects of serotonergic drugs in mice |
| Q58700862 | It's Tea Time: Interference of Ayahuasca Brew on Discriminative Learning in Zebrafish |
| Q36844764 | Modification of 5-methoxy-N,N-dimethyltryptamine-induced hyperactivity by monoamine oxidase A inhibitor harmaline in mice and the underlying serotonergic mechanisms |
| Q92120747 | N,N-dimethyltryptamine Prevents Renal Ischemia-Reperfusion Injury in a Rat Model |
Search more.